Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma

The NAD(+)-metabolizing ectoenzyme CD38 is an established therapeutic target in multiple myeloma. The CD38-specific monoclonal antibodies daratumumab and isatuximab show promising results in the clinic. Nanobodies correspond to the single variable domains (VHH) derived from heavy chain antibodies th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bannas, Peter, Koch-Nolte, Friedrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232533/
https://www.ncbi.nlm.nih.gov/pubmed/30459772
http://dx.doi.org/10.3389/fimmu.2018.02559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232533/
https://www.ncbi.nlm.nih.gov/pubmed/30459772
http://dx.doi.org/10.3389/fimmu.2018.02559

Ejemplares similares